Literature DB >> 17680562

Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis.

Diego F Calvisi1, Maria M Simile, Sara Ladu, Rossella Pellegrino, Valentina De Murtas, Federico Pinna, Maria L Tomasi, Maddalena Frau, Patrizia Virdis, Maria R De Miglio, Maria R Muroni, Rosa M Pascale, Francesco Feo.   

Abstract

Mounting evidence underlines the role of genomic hypomethylation in the generation of genomic instability (GI) and tumorigenesis, but whether DNA hypomethylation is required for hepatocellular carcinoma (HCC) development and progression remains unclear. We investigated the correlation between GI and DNA methylation, and influence of methionine metabolism deregulation on these parameters and hepatocarcinogenesis in c-Myc and c-Myc/Tgf-alpha transgenic mice and human HCCs. S-adenosyl-L-methionine/S-adenosylhomocysteine ratio and liver-specific methionine adenosyltransferase (MatI/III) progressively decreased in dysplastic and neoplastic liver lesions developed in c-Myc transgenic mice and in human HCC with better (HCCB) and poorer (HCCP) prognosis (based on patient's survival length). Deregulation of these parameters resulted in a rise of global DNA hypomethylation both in c-Myc and human liver lesions, positively correlated with GI levels in mice and humans, and inversely correlated with the length of survival of HCC patients. No changes in MATI/III and DNA methylation occurred in c-Myc/Tgf-alpha lesions and in a small human HCC subgroup with intermediate prognosis, where a proliferative activity similar to that of c-Myc HCC and HCCB was associated with low apoptosis. Upregulation of genes involved in polyamine synthesis, methionine salvage and downregulation of polyamine negative regulator OAZ1, was highest in c-Myc/Tgf-alpha HCCs and HCCP. Our results indicate that alterations in the activity of MAT/I/III, and extent of DNA hypomethylation and GI are prognostic markers for human HCC. However, a small human HCC subgroup, as c-Myc/Tgf-alpha tumors, may develop in the absence of alterations in DNA methylation. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680562     DOI: 10.1002/ijc.22940

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

Review 1.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.

Authors:  Maria M Simile; Graziella Peitta; Maria L Tomasi; Stefania Brozzetti; Claudio F Feo; Alberto Porcu; Antonio Cigliano; Diego F Calvisi; Francesco Feo; Rosa M Pascale
Journal:  Oncotarget       Date:  2019-04-19

3.  An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis.

Authors:  Maddalena Frau; Maria M Simile; Maria L Tomasi; Maria I Demartis; Lucia Daino; Maria A Seddaiu; Stefania Brozzetti; Claudio F Feo; Giovanni Massarelli; Giuliana Solinas; Francesco Feo; Ju-Seog Lee; Rosa M Pascale
Journal:  Cell Oncol (Dordr)       Date:  2012-03-21       Impact factor: 6.730

4.  Forced expression of methionine adenosyltransferase 1A in human hepatoma cells suppresses in vivo tumorigenicity in mice.

Authors:  Jiaping Li; Komal Ramani; Zhanfeng Sun; Chishing Zee; Edward G Grant; Heping Yang; Meng Xia; Pilsoo Oh; Kwangsuk Ko; José M Mato; Shelly C Lu
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

5.  Methionine adenosyltransferases in liver health and diseases.

Authors:  Komal Ramani; Shelly C Lu
Journal:  Liver Res       Date:  2017-09

Review 6.  Deregulation of methionine metabolism as determinant of progression and prognosis of hepatocellular carcinoma.

Authors:  Rosa M Pascale; Claudio F Feo; Diego F Calvisi; Francesco Feo
Journal:  Transl Gastroenterol Hepatol       Date:  2018-06-29

7.  A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Authors:  Timothy R Morgan; Kathryn Osann; Teodoro Bottiglieri; Neville Pimstone; John C Hoefs; Ke-Qin Hu; Tarek Hassanein; Thomas D Boyer; Lorene Kong; Wen-Pin Chen; Ellen Richmond; Rachel Gonzalez; Luz M Rodriguez; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-30

8.  Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma.

Authors:  Masahiro Shitani; Shigeru Sasaki; Noriyuki Akutsu; Hideyasu Takagi; Hiromu Suzuki; Masanori Nojima; Hiroyuki Yamamoto; Takashi Tokino; Koichi Hirata; Kohzoh Imai; Minoru Toyota; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2012-03-29

Review 9.  S-adenosylmethionine in liver health, injury, and cancer.

Authors:  Shelly C Lu; José M Mato
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

10.  Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry.

Authors:  Ming-Luan Chen; Fan Shen; Wei Huang; Jia-Hui Qi; Yinsheng Wang; Yu-Qi Feng; Song-Mei Liu; Bi-Feng Yuan
Journal:  Clin Chem       Date:  2013-01-23       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.